Patent Win Unlocks New Era for Cancer Therapy and Market Competition

BOSTON, MA – June 18, 2026 – A landmark court decision has cleared a critical path for a new targeted cancer therapy to enter the U.S. market, signaling a significant shift in the competitive landscape of nuclear medicine. In a ruling issued yesterday, the Delaware U.S. District Court handed radiopharmaceutical leader Curium a decisive victory in its patent dispute with Novartis subsidiary Advanced Accelerator Applications (AAA).

Justice Noreika adjudicated that all relevant patent claims asserted by Novartis concerning its blockbuster therapy were invalid and not infringed upon by Curium’s Lutetium Lu 177 dotatate product. The ruling, described by Curium as a “complete victory,” effectively dismantles a major legal barrier, enabling the company to proceed with plans to commercialize its own therapy for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a rare and complex group of cancers.

This development is more than just a corporate win; it represents a potential turning point for patient access, market dynamics, and the broader field of theranostics—an innovative approach that pairs diagnostic imaging with targeted radiation therapy.

The Battle for a Breakthrough Therapy

The legal confrontation has been a focal point in the rapidly growing radiopharmaceutical sector. The dispute centered on three key Novartis patents (US10596276B2, US10596278B2, and US11904027B2) related to “stable, concentrated radionuclide complex solutions,” the technological underpinning of Novartis’s highly successful drug, Lutathera. Novartis initiated litigation in late 2024 after Curium filed a New Drug Application with the FDA for its competing product, signaling its intent to enter the lucrative U.S. market.

The case, Advanced Accelerator Applications USA, Inc. et al v. Curium US LLC et al, culminated in a bench trial last December. The invalidation of these patents is a significant blow to Novartis's efforts to protect its market dominance. The Swiss pharmaceutical giant has been actively defending its intellectual property against multiple competitors, reflecting the high stakes involved. The market for radioligand therapies, which Novartis itself estimates could be worth $28 billion, is one of the brightest spots in modern oncology.

“We are pleased with the court’s decision,” said Renaud Dehareng, Curium’s group chief executive officer, in a statement. “Curium is focused on building a durable theranostics platform that pairs our diagnostic leadership with targeted radioligand therapies — and doing so with the operational discipline required to serve patients reliably at scale.”

A New Horizon for Neuroendocrine Tumor Patients

For the thousands of patients diagnosed with GEP-NETs each year, the introduction of a new therapeutic option is welcome news. These tumors, which arise from neuroendocrine cells in the pancreas or gastrointestinal tract, are notoriously difficult to treat, especially once they have spread. For years, the standard of care has included surgery, hormone therapy, and, since its FDA approval in 2018, Novartis’s Lutathera.

Lutathera was a game-changer, becoming the first radiopharmaceutical approved for GEP-NETs and generating over $816 million in sales for Novartis in 2025. By binding to receptors on neuroendocrine tumor cells, it delivers a targeted dose of radiation, destroying cancer cells while largely sparing healthy tissue. However, a market dominated by a single therapy can present challenges related to cost, access, and supply.

The entry of Curium’s Lutetium Lu 177 dotatate promises to introduce much-needed competition. While radiopharmaceuticals are inherently complex and expensive to produce, the presence of a second supplier could help stabilize supply chains and provide clinicians and healthcare systems with more choice. “This outcome brings Curium a step closer in our mission to deliver what patients, clinicians and health systems need: timely access to critical targeted radiopharmaceuticals,” commented Michael Patterson, Curium’s North American CEO.

The Complex Logistics of Nuclear Medicine

Bringing a radiopharmaceutical to market is not merely a matter of winning in court; it requires mastering a daunting logistical ballet. The active ingredient, Lutetium-177, is a radioactive isotope with a short half-life of just under seven days. This means the therapy must be manufactured, shipped, and administered to a patient within a very narrow window—often just 72 hours—demanding a flawless, just-in-time supply chain.

Any disruption, from manufacturing hiccups to shipping delays, can mean a patient misses a critical treatment cycle. Novartis itself faced supply constraints in 2022 as demand for its radioligand therapies soared, prompting a rapid expansion of its production network. This high bar for reliability is a major hurdle for any new market entrant.

Curium, however, is positioning itself as uniquely prepared for this challenge. Touting a heritage in nuclear medicine stretching back over a century, the company operates a global network across 70 countries with four major manufacturing sites. It has made strategic investments to secure its Lutetium-177 supply, including the acquisition of nuclear medicine specialist Monrol, to ensure it can meet demand “reliably at scale.” This vertical integration, from isotope production to final product delivery, is central to its strategy to compete effectively and ensure patients receive their treatments on time.

Theranostics and the Future of Cancer Care

This patent victory is a crucial step in Curium’s larger ambition to become a leader in theranostics. This cutting-edge medical paradigm uses radioactive drugs for both diagnosis and therapy—in essence, to “find and fight” cancer. A diagnostic scan first confirms that a patient’s tumors have the right molecular target, and a subsequent therapeutic dose, using a more powerful isotope attached to the same targeting molecule, delivers the treatment.

With a 30-year history of supplying diagnostic products for the neuroendocrine tumor community, Curium is now poised to close the loop by providing the therapeutic component. This victory bolsters its platform and provides momentum for its late-stage pipeline, which includes investigational drugs for other cancers, such as prostate cancer.

The convergence of diagnostics and targeted therapy represents one of the most promising frontiers in oncology. By enabling highly personalized treatments, theranostics holds the potential to improve outcomes and reduce side effects. Curium's successful challenge to an established market leader demonstrates that the landscape of innovation is dynamic, driven not only by scientific discovery but also by the strategic and legal maneuvering that ultimately shapes how these powerful new technologies reach the patients who need them most.